LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Madrigal Pharmaceuticals Inc

Fechado

SetorSaúde

282.16 -4.34

Visão Geral

Variação de preço das ações

24h

Atual

Mín

279.44

Máximo

298.69

Indicadores-chave

By Trading Economics

Rendimento

-14M

-73M

Vendas

34M

137M

EPS

-3.32

Margem de lucro

-53.361

Funcionários

528

EBITDA

-14M

-70M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+43.92% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-512M

6.8B

Abertura anterior

286.5

Fecho anterior

282.16

Sentimento de Notícias

By Acuity

37%

63%

152 / 382 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2025, 23:20 UTC

Ganhos

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 de mai. de 2025, 23:48 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 de mai. de 2025, 23:43 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de mai. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 de mai. de 2025, 23:24 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

13 de mai. de 2025, 23:24 UTC

Conversa de Mercado
Ganhos

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 de mai. de 2025, 22:58 UTC

Ganhos

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 de mai. de 2025, 22:58 UTC

Ganhos

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 de mai. de 2025, 22:58 UTC

Ganhos

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 de mai. de 2025, 22:58 UTC

Ganhos

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 de mai. de 2025, 22:38 UTC

Ganhos

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 de mai. de 2025, 22:38 UTC

Ganhos

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 de mai. de 2025, 22:37 UTC

Ganhos

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 de mai. de 2025, 22:36 UTC

Ganhos

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 de mai. de 2025, 22:35 UTC

Ganhos

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 de mai. de 2025, 22:34 UTC

Ganhos

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 de mai. de 2025, 22:33 UTC

Ganhos

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 de mai. de 2025, 22:33 UTC

Ganhos

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 de mai. de 2025, 22:33 UTC

Ganhos

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 de mai. de 2025, 22:30 UTC

Ganhos

Aristocrat Interim Dividend 44 Australian Cents/Share

13 de mai. de 2025, 22:30 UTC

Ganhos

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 de mai. de 2025, 22:29 UTC

Ganhos

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 de mai. de 2025, 22:28 UTC

Ganhos

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 de mai. de 2025, 21:15 UTC

Ganhos

Nu Holdings 1Q Rev $3.2B >NU

13 de mai. de 2025, 21:03 UTC

Principais Notícias

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

13 de mai. de 2025, 20:32 UTC

Ganhos

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 de mai. de 2025, 20:31 UTC

Ganhos

Alcon 1Q Sales $2.45B >ALC.EB

13 de mai. de 2025, 20:30 UTC

Ganhos

Alcon 1Q Rev $2.47B >ALC.EB

13 de mai. de 2025, 20:30 UTC

Ganhos

Alcon 1Q EPS 70c >ALC.EB

Comparação entre Pares

Variação de preço

Madrigal Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

43.92% parte superior

Previsão para 12 meses

Média 425.08 USD  43.92%

Máximo 539 USD

Mínimo 248 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Madrigal Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

12

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

263.2 / 277.1Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

152 / 382 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.